Company Overview and News

 
International duty-free players to participate in KLIA retail tender

59m theedgemarkets
IT looks like the duty-free shopping scene at the Kuala Lumpur International Airport is getting a major refurbishment, with global players such as Dubai-based Flemingo International and Dufry AG said to be keen to bid for some of the new spaces available for lease.
MYPRY 5SO 9601 5014

 
Valuations already ‘stretched’ for consumer stocks

2018-09-18 theedgemarkets
KUALA LUMPUR: Valuations of consumer stocks jumped to near historical highs after the 14th general election as consumer sentiment rebounded, and as Malaysians got to enjoy an unprecedented three-month tax holiday while the new government prepared the country’s transition to a new tax regime with the zero-rating of the goods and services tax (GST).
MYPRY 5014

 
‘Don’t design airport based on a single airline’s demands’

2018-09-18 theedgemarkets
KUALA LUMPUR: The need for more low-cost carrier terminals (LCCTs) in the country, which has been the subject of much debate for several years, heated up after former Penang chief minister Lim Guan Eng was reported in the press last month as saying that the federal government was in talks with AirAsia Group Bhd and Malaysia Airports Holdings Bhd (MAHB) to build an LCCT in Penang.
MYPRY 5014

 
KLCI falls 0.57% as Trump slaps more tariffs on Chinese goods

2018-09-18 theedgemarkets
KUALA LUMPUR (Sept 18): The FBM KLCI got off to a poor start upon resuming trade this morning after the extended weekend and fell 0.57% in line with the global markets that came under pressure after US President Donald Trump slapped further tariffs on China.
TGLVY 1023 7052 PBLOF 7113 MYPRY TPGVF 2836 1295 5014 CIMDF

 
Newsbreak: Full-service carriers cry foul over ‘unfair’ PSC practice

2018-09-17 theedgemarkets
FULL-service carriers (FSCs) have finally broken their silence over the non-compliance of their budget counterpart, AirAsia Group Bhd, with the new passenger service charge (PSC), also known as airport tax, out of klia2 in Sepang.
MYPRY 5014

 
Strong international air travel expected to continue for Malaysia Airports Holdings

2018-09-14 theedgemarkets
Malaysia Airports Holdings Bhd (Sept 13, RM9.04) Maintain neutral with an unchanged target price (TP) of RM9.88: The August passenger traffic for airports in Malaysia saw
MYPRY 5014

 
MAHB edges lower in early trade

2018-09-14 thestar.com.my
KUALA LUMPUR: Malaysia Airports Holdings Bhd ’s (MAHB) shares were lower in early trade Friday as investors take profit after the recent gains.
MYPRY 5014

 
MAHB consolidating, says AllianceDBS Research

2018-09-13 theedgemarkets
KUALA LUMPUR (Sept 13): AllianceDBS Research said Malaysia Airports Holdings Bhd (Airport) had on Sept 13 traded within previous day’s range to form an inside day bar before closing near the day’s low at RM9.04 (down 21 sen or 2.27%).
MYPRY 5014

 
KLCI recovers to erase earlier loss in line with region

2018-09-13 theedgemarkets
KUALA LUMPUR (Sept 13): The FBM KLCI recovered at midday break, erasing earlier losses, climbing in line with regional peers.
HLFBF UPBMF 7036 1082 BATS 4162 0096 2089 5014 CIMDF 0166 5139 1023 1368 0900 5819 MYPRY 2836

 
MAHB airport traffic grew 2.9% y-o-y in August

2018-09-13 theedgemarkets
KUALA LUMPUR: Malaysia Airports Holdings Bhd’s (MAHB) network of airports served 11.78 million passengers in August this year, up 2.9% year-on-year (y-o-y), largely due to growth in passenger movements at its Istanbul Sabiha Gokcen International Airport (SGIA) in Turkey.
MYPRY 5014

 
MAHB airport traffic grew 2.9% y-o-y in August

2018-09-12 theedgemarkets
KUALA LUMPUR (Sept 12): Malaysia Airports Holdings Bhd (MAHB)'s network of airports served 11.78 million passengers in August this year, up 2.9% year-on-year, largely due to growth in passenger movements at its Istanbul Sabiha Gokcen International Airport (SGIA) in Turkey.
MYPRY 5014

 
MAHB records 2.9pc passenger growth in Aug 2018

2018-09-12 malaymail
KUALA LUMPUR, Sept 12 — Malaysia Airports Holdings Bhd’s (MAHB) network of airports recorded 11.8 million passengers in August 2018, a 2.9 per cent year-on-year (y-o-y) growth.
MYPRY BSMAF 5014 1818

 
Fernandes: AirAsia needs MAHB's support to make Malaysia a logistics hub

2018-09-07 theedgemarkets
KUALA LUMPUR (Sept 7): Low cost carrier AirAsia Group Bhd's Tan Sri Tony Fernandes said the group's logistics businesses, operated via RedCargo Logistics Sdn Bhd, requires the support of Malaysia Airports Holdings Bhd in order to make the country a logistics hub.
MYPRY BSMAF 5014 1818

 
KLCI remains under pressure, struggles to defend 1,800-level

2018-09-07 theedgemarkets
KUALA LUMPUR (Sept 7): The FBM KLCI remained under pressure at midday break today and struggled to defend its 1,800-point level.
HLFBF UPBMF 7036 1082 7113 TPGVF BATS 4162 0096 7087 5168 2089 5014 7123 TGLVY 3026 3867 1368 MYPRY 2836 GEBHF 3719 HRGHY

 
MAHB launches month-long M’sian food & fashion campaign at KLIA

2018-09-07 theedgemarkets
KUALA LUMPUR (Sept 7): Malaysia Airports Holdings Bhd (MAHB) has launched a month-long campaign at KLIA, tagged HIMPUN, to showcase the best of Malaysian fashion, craft, delicacies and beauty products to a global audience.
MYPRY 5014

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 56108G107